ENDRA Life Sciences Inc. (NDRA): restructuring charge — ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K

ENDRA Life Sciences Inc.

Reduced headcount on March 19, 2026; expects ~$51K in severance charges in Q1 2026.
Board initiated review of strategic alternatives including mergers, asset sales, or sale of company.
Engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel.
No timetable set for process; will continue executing TAEUS business priorities.

item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.7

ENDRA Life Sciences Inc. announced a restructuring with charges of approximately $51,000.

Type: restructuring
Charge: approximately $51,000

Exact text from the filing

on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with severance payments to former employees.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-033878

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.